Cargando…
Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study
This case study highlights the dynamic nature of the antibody response to SARS-CoV-2 in a vulnerable subject aged 70 years between 2021 and 2023. This individual had been vaccinated with six doses of the ancestral (Wuhan-Hu-1) COVID-19 vaccine and had a breakthrough infection 126 days after receivin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507991/ https://www.ncbi.nlm.nih.gov/pubmed/37731681 http://dx.doi.org/10.7759/cureus.45531 |
_version_ | 1785107433853550592 |
---|---|
author | Kanokudom, Sitthichai Suntronwong, Nungruthai Duangchinda, Thaneeya Wanlapakorn, Nasamon Poovorawan, Yong |
author_facet | Kanokudom, Sitthichai Suntronwong, Nungruthai Duangchinda, Thaneeya Wanlapakorn, Nasamon Poovorawan, Yong |
author_sort | Kanokudom, Sitthichai |
collection | PubMed |
description | This case study highlights the dynamic nature of the antibody response to SARS-CoV-2 in a vulnerable subject aged 70 years between 2021 and 2023. This individual had been vaccinated with six doses of the ancestral (Wuhan-Hu-1) COVID-19 vaccine and had a breakthrough infection 126 days after receiving Covovax™ (CO) as the sixth dose. The serostatus for total immunoglobulin specific to the receptor binding domain (total RBD Ig) changed from negative to positive following a two-dose CoronaVac (CV) vaccination, indicating a successful immune response. Booster doses, including AZD1222 (AZ), half-dose BNT162b2 (PF), and CO, increased the total RBD Ig levels, except for CV. The individual experienced a breakthrough infection by the Omicron BA.5 variant, leading to a substantial surge in total RBD Ig to over 10(5) U/mL. This generated sustained and extended antibody persistence, with the half-life of total RBD Ig lasting approximately 103.6 days. Furthermore, it has been observed that this breakthrough infection generated the highest neutralizing antibodies against BA.5, followed by XBB.1.5, BQ.1.1, and BA.2.75, respectively. |
format | Online Article Text |
id | pubmed-10507991 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-105079912023-09-20 Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study Kanokudom, Sitthichai Suntronwong, Nungruthai Duangchinda, Thaneeya Wanlapakorn, Nasamon Poovorawan, Yong Cureus Allergy/Immunology This case study highlights the dynamic nature of the antibody response to SARS-CoV-2 in a vulnerable subject aged 70 years between 2021 and 2023. This individual had been vaccinated with six doses of the ancestral (Wuhan-Hu-1) COVID-19 vaccine and had a breakthrough infection 126 days after receiving Covovax™ (CO) as the sixth dose. The serostatus for total immunoglobulin specific to the receptor binding domain (total RBD Ig) changed from negative to positive following a two-dose CoronaVac (CV) vaccination, indicating a successful immune response. Booster doses, including AZD1222 (AZ), half-dose BNT162b2 (PF), and CO, increased the total RBD Ig levels, except for CV. The individual experienced a breakthrough infection by the Omicron BA.5 variant, leading to a substantial surge in total RBD Ig to over 10(5) U/mL. This generated sustained and extended antibody persistence, with the half-life of total RBD Ig lasting approximately 103.6 days. Furthermore, it has been observed that this breakthrough infection generated the highest neutralizing antibodies against BA.5, followed by XBB.1.5, BQ.1.1, and BA.2.75, respectively. Cureus 2023-09-19 /pmc/articles/PMC10507991/ /pubmed/37731681 http://dx.doi.org/10.7759/cureus.45531 Text en Copyright © 2023, Kanokudom et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Allergy/Immunology Kanokudom, Sitthichai Suntronwong, Nungruthai Duangchinda, Thaneeya Wanlapakorn, Nasamon Poovorawan, Yong Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study |
title | Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study |
title_full | Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study |
title_fullStr | Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study |
title_full_unstemmed | Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study |
title_short | Dynamic Antibody Response and Hybrid Immunity Following Multiple COVID-19 Vaccine Doses and Infection: A Case Study |
title_sort | dynamic antibody response and hybrid immunity following multiple covid-19 vaccine doses and infection: a case study |
topic | Allergy/Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507991/ https://www.ncbi.nlm.nih.gov/pubmed/37731681 http://dx.doi.org/10.7759/cureus.45531 |
work_keys_str_mv | AT kanokudomsitthichai dynamicantibodyresponseandhybridimmunityfollowingmultiplecovid19vaccinedosesandinfectionacasestudy AT suntronwongnungruthai dynamicantibodyresponseandhybridimmunityfollowingmultiplecovid19vaccinedosesandinfectionacasestudy AT duangchindathaneeya dynamicantibodyresponseandhybridimmunityfollowingmultiplecovid19vaccinedosesandinfectionacasestudy AT wanlapakornnasamon dynamicantibodyresponseandhybridimmunityfollowingmultiplecovid19vaccinedosesandinfectionacasestudy AT poovorawanyong dynamicantibodyresponseandhybridimmunityfollowingmultiplecovid19vaccinedosesandinfectionacasestudy |